Wide Ranks

CKPT

Checkpoint Therapeutics, Inc.

4.28

Top Statistics
Market Cap 209 M Forward PE -23.78 Revenue Growth 32.30 %
Current Ratio 0.27 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue 1927.70 Price To Sales Trailing12 Months 2679.53
Profitability
Profit Margins 0.00 % Operating Margins -16275.61 %
Balance Sheet
Total Cash 4 M Total Cash Per Share 0.1100 Total Debt
Total Debt To Equity Current Ratio 0.27 Book Value Per Share -0.4700
All Measures
Short Ratio 570.00 % Message Board Id finmb_286675384 Fax 646 619 4950
Shares Short Prior Month 4 M City Waltham Uuid 0b6333fa-c8dd-3277-b59f-9dbaa499e00b
Previous Close 4.10 First Trade Date Epoch Utc 1 B Book Value -0.4700
Beta 1.24 Volume 974294 Last Split Date 1 B
Fifty Two Week Low 1.36 Total Cash Per Share 0.1100 Total Revenue 78000
Shares Short Previous Month Date 1 B Target Median Price 20.00 Max Age 86400
Recommendation Mean 1.33 Sand P52 Week Change 0.3133 Operating Margins -16275.61 %
Target Mean Price 17.00 Net Income To Common -42467000 Short Percent Of Float 0.1337
Implied Shares Outstanding 48 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 1 M Average Volume10days 1 M Total Cash 4 M
Next Fiscal Year End 1 B Revenue Per Share 0.0020 Held Percent Insiders 0.1552
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 4.10 Target Low Price 4.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 3.04 Open 4.10 Free Cashflow -28931876
State MA Dividend Yield 0.00 % Return On Assets -3.17
Time Zone Short Name EST Trailing Eps -1.83 Day Low 4.05
Address1 95 Sawyer Road Shares Outstanding 48 M Price Hint 4
Target High Price 27.00 Website https://checkpointtx.com 52 Week Change 0.6090
Average Volume 750489 Forward Eps -0.1800 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 23.30 % Last Split Factor 1:10
Regular Market Day High 4.32 Is_sp_500 False Profit Margins 0.00 %
Fifty Two Week High 4.33 Day High 4.32 Shares Short 5 M
Regular Market Open 4.10 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 1927.70 Revenue Growth 32.30 % Shares Percent Shares Out 0.1236
Operating Cashflow -34297000 Currency USD Time Zone Full Name America/New_York
Market Cap 209 M Is_nasdaq_100 False Zip 02453
Quote Type EQUITY Industry Biotechnology Long Name Checkpoint Therapeutics, Inc.
Regular Market Day Low 4.05 Held Percent Institutions 0.1391 Current Price 4.28
Address2 Suite 110 Financial Currency USD Current Ratio 0.27
Industry Disp Biotechnology Number Of Analyst Opinions 3 Country United States
Float Shares 34 M Two Hundred Day Average 2.28 Enterprise Value 150 M
Price To Sales Trailing12 Months 2679.53 Forward PE -23.78 Regular Market Volume 974294
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally.

The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.

It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.

The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with GC Cell.

The company was incorporated in 2014 and is based in Waltham, Massachusetts.

Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.